Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, discusses the process of cataract development and its prevalence in both older and younger populations.
Occurring naturally over time, cataracts can develop in both older and younger populations, particularly those with diabetes or prior eye injuries, said Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision.
Transcript
Can you discuss the prevalence of cataracts among adults in the United States?
Cataracts, as you probably know, are a natural clouding of the lens of the eye. It happens naturally as we age, and it's estimated that by age 75, approximately half of all Americans have cataracts. And cataracts continue to develop as we get older.
There are some reasons that a cataract can develop at an earlier age. For example, if patients are on certain medications, if they're diabetic, if they have a family history of cataracts, or sometimes if they've had significant injuries around the eyes. There are multiple reasons that we look for cataracts at an earlier age, as well.
What trends are you seeing in the development of cataracts?
Certainly, as we all have greater visual needs, we are finding that the age for cataract surgery is occurring at an earlier age in life, because ultimately cataracts decrease vision. So, if we're doing more visually, then we notice that earlier, but the trends in general are still similar.
It's related to those medical conditions or family history at an early age, but otherwise, it's primarily related to age. And it's thought that it’s that natural process of the lens becoming more dense and cloudy, which is really what a cataract is.
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Bimekizumab Poised to Tackle Unmet HS Treatment Needs
October 18th 2024Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.
Read More